Impact Factor
3.31
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.72
13,772 total citations
h5-index
142
h5 depth signal
Cited share
23.9%
2,004 of 8,393
Total citations
13,772
Citation footprint
Metric signal
1.71
External metric anchor
Self-citation
1.4%
190 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
6,013
Japan
3,690
China
3,561
Italy
3,495
France
3,193
Citing Fields of Research
Oncology
19,103
Lung Cancer
7,903
Immunology
7,706
Liver & Colon Cancer
6,573
Breast Cancer
6,057
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
65,667
Articles tracked across the journal lifetime
Indexed publication set
8,393
2,004 cited publications
Last 12 months
5,509
459.1 publications/month
Open access share
1.3%
70 OA publications in the last year
Leading citing country
United States
6,013 citing publications
Leading citing field
Oncology
19,103 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1990-
v1n1, 1990-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Lung Cancer
Liver & Colon Cancer
Immunology
Breast Cancer
Issuing & Sponsoring Bodies
Contributor
European Society for Medical Oncology
Broad Categories
Neoplasms
Lung Cancer
Liver & Colon Cancer
Digestive Disorders
Immunology
Breast Cancer
Urology
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/j.annonc.2026.07.362
Open DOI
P101-6 Molecular subtypes of advanced pulmonary large cell neuroendocrine carcinoma treated with immune checkpoint inhibitors
02
DOI 10.1016/j.annonc.2026.07.358
Open DOI
P098-12 Nivolumab in advanced NSCLC as first-line combination vs. second-line monotherapy: systematic review and meta-analysis
03
DOI 10.1016/j.annonc.2026.07.357
Open DOI
P098-11 Assessing efficacy and safety of pembrolizumab combined with chemoradiation in NSCLC: a systematic review
04
DOI 10.1016/j.annonc.2026.07.356
Open DOI
P097-9 Richter transformation of CLL to diffuse large B-cell lymphoma: a case report and review of literature
05
DOI 10.1016/j.annonc.2026.07.355
Open DOI
P097-7 Polatuzumab vedotin as second-line therapy for recurrent primary cutaneous B-cell lymphoma in an elderly: a case report
06
DOI 10.1016/j.annonc.2026.07.354
Open DOI
P096-8 Two cases of chronic myelomonocytic leukemia analyzed by a gene panel test for hematologic malignancies
07
DOI 10.1016/j.annonc.2026.07.353
Open DOI
P096-7 Concurrent use of imatinib and pembrolizumab in a patient with CML and lung adenocarcinoma: a case report
08
DOI 10.1016/j.annonc.2026.07.352
Open DOI
P096-2 Challenging presentation of Hodgkin lymphoma with overlapping life-threatening conditions: a case report
09
DOI 10.1016/j.annonc.2026.07.345
Open DOI
P089-7 Association between geriatric assessment and initial treatment intensity in older adults with cancer
10
DOI 10.1016/j.annonc.2026.07.344
Open DOI
P089-2 Polypharmacy and potentially inappropriate medications in geriatric oncology: real-world evidence from Thailand
Bibliographical & Catalog Notes
Title from cover.
Some supplements online only.
Supplements accompany issues.
Also issued online.
Companion journal to: ESMO open.
Complemented by (work): ESMO open 2059-7029 (DLC) 2016243397 (OCoLC)959619462.
Vol. 1, no. 1 (1990)19910103 Notice published Printed on acid-free paper